Several studies have shown that HSP90 inhibitors disrupt mitochondrial integrity in various cancer cells, including neuroblastoma, cervical cancer, glial and prostate cancer cells, leading to apoptosis accompanied by the loss of mitochondrial membrane potential and the generation of oxidative stress 37, 38. This evidence concerns the gene HSP90AA1 and cervical cancer.